Literature DB >> 19949390

Targeting RNA: an emerging hope for treating muscular dystrophy.

Andy Extance.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19949390     DOI： 10.1038/nrd3069

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  4 in total

1.  pH-Sensitive siRNA nanovector for targeted gene silencing and cytotoxic effect in cancer cells.

Authors:  Hyejung Mok; Omid Veiseh; Chen Fang; Forrest M Kievit; Freddy Y Wang; James O Park; Miqin Zhang
Journal:  Mol Pharm       Date:  2010-09-14       Impact factor: 4.939

2.  Antisense mediated exon skipping therapy for duchenne muscular dystrophy (DMD).

Authors:  Camilla Brolin; Takehiko Shiraishi
Journal:  Artif DNA PNA XNA       Date:  2011-01

3.  Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.

Authors:  Limin Cao; Gang Han; Ben Gu; HaiFang Yin
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

4.  Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay.

Authors:  Laura Lentini; Raffaella Melfi; Aldo Di Leonardo; Angelo Spinello; Giampaolo Barone; Andrea Pace; Antonio Palumbo Piccionello; Ivana Pibiri
Journal:  Mol Pharm       Date:  2014-02-07       Impact factor: 4.939
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.